Condition

Symptomatic Neurogenic Orthostatic Hypotension

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting0

Common interventions5

Lead sponsors shown3

Clinical trials

5 shown

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT04095793 · 2019-09-19

TERMINATED

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT03829657 · 2019-02-22

TERMINATED

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT03750552 · 2019-01-24

COMPLETED

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic HypotensionNCT02586623 · 2016-02-11

COMPLETED

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa TherapyNCT01927055 · 2013-11-01

TERMINATED

Common interventions

ampreloxetineDRUG3 PlaceboDRUG3 DroxidopaDRUG1 Droxidopa capsulesDRUG1 Placebo capsulesDRUG1

Leading sponsors

Theravance Biopharma 3 Chelsea Therapeutics 1 H. Lundbeck A/S 1

Trial status mix

TERMINATED3

COMPLETED2

Phase mix

PHASE34

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.